益肾活血提取液对同型半胱氨酸诱导的兔血管平滑肌细胞增殖作用的实验研究
|
摘要
目的
1.观察益肾活血提取液对同型半胱氨酸诱导的兔血管平滑肌细胞增殖的影响;
2.观察益肾活血提取液对NF-κzB活化、TGF-β_1、MCP-1、VCAM-1和PCNA的表达及细胞周期的影响:
3.探讨NF-κB信号转导通路的调节对兔血管平滑肌细胞增殖的可能机制。
方法
采用组织贴块法培养原代兔血管平滑肌细胞,并通过差速贴壁法进行纯化。倒置显微镜下观察细胞形态及生长现象,SP法行a-SM-actin免疫细胞化学染色鉴定,细胞纯度达95%以上,取处于对数生长期的第3～6代细胞用于实验。建立同型半胱氨酸诱导(终浓度1mM)的细胞增殖模型,实验共分6组,空白对照组、模型组均不加益肾活血提取液,实验组细胞培养液中加入不同浓度的益肾活血提取液(终浓度分别为5000、500、50mg/L),西药对照组加入叶酸(终浓度5mM),继续培养24h进行实验检测。采用MTT法检测细胞的增殖活度,流式细胞术检测细胞周期的变化,免疫细胞化学染色检测NF-κBp65活化和TGF-β_1、MCP-1、VCAM-1和PCNA的蛋白表达,RT-PCR检测TGF-β_1、MCP-1、VCAM-1的mRNA表达。实验重复3次,实验数据采用统计学方法进行分析。
结果
1.不同浓度的益肾活血提取液作用24h后,可观察到细胞的异常增殖状态受到抑制。MTT法检测并分析其对细胞增殖的抑制作用,流式细胞仪检测细胞周期的变化,发现实验组细胞处于静止期(G_0/G_1期)的比例增加,处于DNA合成期(S期)和有丝分裂期(G_2/M期)的比例减少,这较之模型组有明显差异(P＜0.01),且表现出剂量依赖性。
2.免疫细胞化学检测显示NF-κBp65和TGF-β_1、MCP-1、VCAM-1、PCNA在平滑肌细胞内的表达及其相互关系:NF-κBp65、PCNA表达阳性产物呈棕褐色颗粒,位于细胞浆/细胞核,TGF-β_1、MCP-1、VCAM-1表达位于细胞浆,亦呈棕褐色颗粒。在益肾活血提取液作用于细胞24h后其表达水平均明显下降,且随着NF-κBp65活化的抑制,TGF-β_1、MCP-1、VCAM-1的表达也随之下调(P＜0.01)。
3.RT-PCR检测分析TGF-β_1、MCP-1、VCAM-1的mRNA表达:不同浓度的益肾活血提取液作用于细胞24h后,TGF-β_1、MCP-1、VCAM-1的mRNA表达明显下调。而且,随着浓度的增加其表达呈逐渐下降的趋势,其中大、中剂量组的下调趋势明显高于西药对照组,相对光密度比值分别为0.46±0.04、0.45±0.05、0.42±0.04(P＜0.01)。
结论
1.益肾活血提取液可以有效地抑制NF-κB的活化,抑制平滑肌细胞的异常增殖,调节细胞周期,表现出剂量依赖效应;
2.NF-κB的活性下调的同时,TGF-β_1、MCP-1、VCAM-1及PCNA等的表达也随之下调,且与NF-κB活化密切正相关;
3.益肾活血提取液能有效地抑制NF-κB的活化,其对TGF-β_1、MCP-1、VCAM-1及PCNA等多种因子表达的影响可能是通过干扰基因的转录来实现的。
Objectives
1.To investigate the effects of Yishenhuoxue Capsule on proliferative rabbits' vascular smooth muscle cells induced by HCY.
2.To investigate the effects of Yishenhuoxue Capsule on NF-κB activation、the expression of TGF-β_1、MCP-1、VCAM-1、PCNA and cell cycles.
3.To explore the potential mechanism of modulating the NF-κB signal transduction pathway on proliferative rabbits'vascular smooth muscle cells induced by HCY.
Methods
VSMCs were cultured by tissue explants in vitro and pured by the difference of adherent rate.Celluar morphology and growth nature were observed with inverted microscope.After identified with a-SM-actin by SP,the purity of cells was greater than 95%,then cells in logarithmic phase from 3 generation to 6 were used to test. Proliferative cells were induced by HCY(1mM),next they were divided into 6 groups-the control group(no HCY)、the HCY group and four treatment groups(5000、500、50mg/L YSHXC,5mM folic acid respectively),and then tested after 24 hours culture.The proliferation of cells and cell cycles were determined by MTT and flow cytometry;the expressions of TGF-β_1、MCP-1、VCAM-1、PCNA and NF-κB activation were detected and analyzed with immunocytochemistry and RT-PCR.All tests were repeated for three times.The data was analyzed by statistics.
Results
1.YSHXC of different concentration could inhibit cells'proliferation.The inhibition and cell cycles detection by MTT and flow cytometry showed that,in treatment groups the number of cells at G_0/G_1 stage increased greatly,while the number at S and G_2/M stages decreased;which was different from the HCY group(P＜0.01).And it also presented dose-dependent.
2.The positive products of NF-κB activation and PCNA showed the brown particles located in cytoplasm and/or nucleus,the ones of TGF-β_1、MCP-1、VCAM-1 expression were mainly located in cytoplasm,which showed brown particles as well. They were downregulated after YSHXC treating for 24 hours.Downregulation of TGF-β_1、MCP-1、VCAM-1 expression were closely correlated with inhibition of NF-κB activation(P＜0.01).
3.RT-PCR analysis showed that,compared with the control group,VSMCs treated with YSHXC at different concentration for 24 hours indicated the decline of TGF-β_1、MCP-1、VCAM-1 expression respectively.And the decline of TGF-β_1、MCP-1、VCAM-1 expression of the YSHXC higherdose and middledose groups was superior to that of the folic acid group 0.46±0.04、0.45±0.05、0.42±0.04(P＜0.01).
Conclusions
1.YSHXC can effectively and dose-dependently inhibit the NF-κB activation, reduce the abnormal proliferation of VSMCs,and adjust the cell cycles.
2.TGF-β_1、MCP-1、VCAM-1、PCNA expression will downregulate accompanied with the inhibition of NF-κB activation,which were closely correlated.
3.Inhibition of NF-κB activation by YSHXC may affect the expressions of TGF-β_1、MCP-1、VCAM-1、PCNA through interfering the gene transcription action.
1.观察益肾活血提取液对同型半胱氨酸诱导的兔血管平滑肌细胞增殖的影响;
2.观察益肾活血提取液对NF-κzB活化、TGF-β_1、MCP-1、VCAM-1和PCNA的表达及细胞周期的影响:
3.探讨NF-κB信号转导通路的调节对兔血管平滑肌细胞增殖的可能机制。
方法
采用组织贴块法培养原代兔血管平滑肌细胞,并通过差速贴壁法进行纯化。倒置显微镜下观察细胞形态及生长现象,SP法行a-SM-actin免疫细胞化学染色鉴定,细胞纯度达95%以上,取处于对数生长期的第3～6代细胞用于实验。建立同型半胱氨酸诱导(终浓度1mM)的细胞增殖模型,实验共分6组,空白对照组、模型组均不加益肾活血提取液,实验组细胞培养液中加入不同浓度的益肾活血提取液(终浓度分别为5000、500、50mg/L),西药对照组加入叶酸(终浓度5mM),继续培养24h进行实验检测。采用MTT法检测细胞的增殖活度,流式细胞术检测细胞周期的变化,免疫细胞化学染色检测NF-κBp65活化和TGF-β_1、MCP-1、VCAM-1和PCNA的蛋白表达,RT-PCR检测TGF-β_1、MCP-1、VCAM-1的mRNA表达。实验重复3次,实验数据采用统计学方法进行分析。
结果
1.不同浓度的益肾活血提取液作用24h后,可观察到细胞的异常增殖状态受到抑制。MTT法检测并分析其对细胞增殖的抑制作用,流式细胞仪检测细胞周期的变化,发现实验组细胞处于静止期(G_0/G_1期)的比例增加,处于DNA合成期(S期)和有丝分裂期(G_2/M期)的比例减少,这较之模型组有明显差异(P＜0.01),且表现出剂量依赖性。
2.免疫细胞化学检测显示NF-κBp65和TGF-β_1、MCP-1、VCAM-1、PCNA在平滑肌细胞内的表达及其相互关系:NF-κBp65、PCNA表达阳性产物呈棕褐色颗粒,位于细胞浆/细胞核,TGF-β_1、MCP-1、VCAM-1表达位于细胞浆,亦呈棕褐色颗粒。在益肾活血提取液作用于细胞24h后其表达水平均明显下降,且随着NF-κBp65活化的抑制,TGF-β_1、MCP-1、VCAM-1的表达也随之下调(P＜0.01)。
3.RT-PCR检测分析TGF-β_1、MCP-1、VCAM-1的mRNA表达:不同浓度的益肾活血提取液作用于细胞24h后,TGF-β_1、MCP-1、VCAM-1的mRNA表达明显下调。而且,随着浓度的增加其表达呈逐渐下降的趋势,其中大、中剂量组的下调趋势明显高于西药对照组,相对光密度比值分别为0.46±0.04、0.45±0.05、0.42±0.04(P＜0.01)。
结论
1.益肾活血提取液可以有效地抑制NF-κB的活化,抑制平滑肌细胞的异常增殖,调节细胞周期,表现出剂量依赖效应;
2.NF-κB的活性下调的同时,TGF-β_1、MCP-1、VCAM-1及PCNA等的表达也随之下调,且与NF-κB活化密切正相关;
3.益肾活血提取液能有效地抑制NF-κB的活化,其对TGF-β_1、MCP-1、VCAM-1及PCNA等多种因子表达的影响可能是通过干扰基因的转录来实现的。
Objectives
1.To investigate the effects of Yishenhuoxue Capsule on proliferative rabbits' vascular smooth muscle cells induced by HCY.
2.To investigate the effects of Yishenhuoxue Capsule on NF-κB activation、the expression of TGF-β_1、MCP-1、VCAM-1、PCNA and cell cycles.
3.To explore the potential mechanism of modulating the NF-κB signal transduction pathway on proliferative rabbits'vascular smooth muscle cells induced by HCY.
Methods
VSMCs were cultured by tissue explants in vitro and pured by the difference of adherent rate.Celluar morphology and growth nature were observed with inverted microscope.After identified with a-SM-actin by SP,the purity of cells was greater than 95%,then cells in logarithmic phase from 3 generation to 6 were used to test. Proliferative cells were induced by HCY(1mM),next they were divided into 6 groups-the control group(no HCY)、the HCY group and four treatment groups(5000、500、50mg/L YSHXC,5mM folic acid respectively),and then tested after 24 hours culture.The proliferation of cells and cell cycles were determined by MTT and flow cytometry;the expressions of TGF-β_1、MCP-1、VCAM-1、PCNA and NF-κB activation were detected and analyzed with immunocytochemistry and RT-PCR.All tests were repeated for three times.The data was analyzed by statistics.
Results
1.YSHXC of different concentration could inhibit cells'proliferation.The inhibition and cell cycles detection by MTT and flow cytometry showed that,in treatment groups the number of cells at G_0/G_1 stage increased greatly,while the number at S and G_2/M stages decreased;which was different from the HCY group(P＜0.01).And it also presented dose-dependent.
2.The positive products of NF-κB activation and PCNA showed the brown particles located in cytoplasm and/or nucleus,the ones of TGF-β_1、MCP-1、VCAM-1 expression were mainly located in cytoplasm,which showed brown particles as well. They were downregulated after YSHXC treating for 24 hours.Downregulation of TGF-β_1、MCP-1、VCAM-1 expression were closely correlated with inhibition of NF-κB activation(P＜0.01).
3.RT-PCR analysis showed that,compared with the control group,VSMCs treated with YSHXC at different concentration for 24 hours indicated the decline of TGF-β_1、MCP-1、VCAM-1 expression respectively.And the decline of TGF-β_1、MCP-1、VCAM-1 expression of the YSHXC higherdose and middledose groups was superior to that of the folic acid group 0.46±0.04、0.45±0.05、0.42±0.04(P＜0.01).
Conclusions
1.YSHXC can effectively and dose-dependently inhibit the NF-κB activation, reduce the abnormal proliferation of VSMCs,and adjust the cell cycles.
2.TGF-β_1、MCP-1、VCAM-1、PCNA expression will downregulate accompanied with the inhibition of NF-κB activation,which were closely correlated.
3.Inhibition of NF-κB activation by YSHXC may affect the expressions of TGF-β_1、MCP-1、VCAM-1、PCNA through interfering the gene transcription action.
引文
1.McCully KS.Homocysteine and vascular disease[J].NatMed,1996,2(4):386-389.
2.Rose R.Atherosclereosis-an inflammatory disease[J].N Eng J Med,1999,340(2):115-126.
3.Wilcken DE,Wilcken B.The pathogenesis of coronary artery disease:A possible role for methionine metabolism[J].J Clin Invest,1976,57(4):1079-1082.
4.司徒镇强.细胞培养[M].西安:世界图书出版公司,2001:69-71.
5.McCully KS.Vascular pathology of homocysteinemia:Implications for the pathologenesis of arteriosclerosis[J].Am J Pathol,1969,56(1):111-128.
6.Laaksonen R,Janatuinen T.High oxidized-LDL and elevated plasma homocysteine contribute to the early reduction of myocardial flow reserve in healthy adults[J].Eur J Clin Invest,2002,32(11):795-802.
7.Boushey C.A quantitative assessment of plasma homocysteine as a risk factor for vascular disease.Probable benefits of increasing folic acid intakes[J].JAMA,1995,274(13):1049-1057.
8.Rolland PH,Friggi A,Barlatier L,et al.Hyperhomocystenemia induced vascular damage in the minipig[J].Circulation,1995,91(14):1161.
9.Morita H,Kurihara H,Yoshida S,et al.Diet-induced hyperhomocysteinemia exacerbates neointima formation in rat carotid arteries after balloon injury[J].Circulation,2001,103(1):133-139.
10.Tsai JC,Perrella MA,Yoshizumi M,et al.Promotion of vascular smooth muscle cell growth by homocysteine:a link to atherosclerosis[J].Proc Natl Acad Sci,1994,91(14):6369-6373.
11.田青平.同型半胱氨酸促平滑肌细胞增殖的信号传递途径[J].中华医学杂志,2000,80(2):25-28.
12.Graham IM,Daly LE,Refsum HM,et al.Plasma homocysteine as a risk factor for vascular disease.The European Concerted Action Project[J].JAMA,1997,277(22):1775-1781.
13.Taylor LM Jr,De Frang RD,Harris EJ Jr,et al.The association of elevated plasma homocysteine with progression of symptomatic peripheral arterial disease[J].J Vasc Surg,1991,13(1):128-136.
14.Danesh J,Lewington S.Plasma homocysteine and coronary artery disease:systematic review of published epidemiological studies[J].J Cardiovasc Risk,1998,5(4):229-232.
15.Nygard O,Vollset SE,Refsum H,et al.Total homocysteineand cardiovascular disease[J].J InternMed,1999,246(5):425-454.
16.Meleady R,Graham I.Plasma homocysteine as a cardiovascular risk factor:causal,consequential,or of no consequence[J].Nutr Rev,1999,57(10):299-305.
17.Shishodia S,Majumdar S,Banerjee S,et al.Ursolic acid inhibits nuclear factor-kappa B activation induced by carcinogenic agents through suppression of I kappaB alpha kinase and p65 phosphorylation:correlation with down-regulation of cyclooxygenase 2,matrixmetalloproteinase 9,and cyclin D1[J].Cancer Res,2003,63(15):4375-4383.
18.史剑慧,许小平,李林,等.核因子-κB活化抑制对化疗药物诱导的P388白血病细胞凋亡的影响[J].中华医学杂志,2002,82(15):1050-1053.
19.Shishodia S,Aggarwal BB.Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation,suppressesexpression of anti-apoptotic gene products,and enhances apoptosis[J].Biol Chem.2004,279(45):47148-47158.
20.Jacobsen EA,Ananieva O,Brown ML,et al.Growth,Differentiation,and Malignant Transformation of Pre-BCells Mediated by Inducible Activation of v-Abl Oncogene[J].Immunol,2006,176(11):6831-6838.
21.Silverman N,Maniatis T.NF-kappa B signaling pathways in mammalian and insect innate immunity[J].Genes Dev,2001,15(18):2321-2342.
22.Flohe L,Brigelius-Flohe R,Saliou C,et al.Packer L redox regulation of NF-kappa B activation[J].Free Raic Biol Med,1997,22(6):1115-1126.
23.May MJ,Ghosh S.Signal transduction through NF-κB[J].Immunol Today,1998,19(2):80-88.
24.Lubec B,Labudova O,Hoeger H,et al.Homocysteine increase cyclin-dependent kinase in aortic rat tissue[J].Circulation,1996,94(20):2620.
25. Wang G, Siow YL, O K. Homocysteine stimulates nuclear factor kappaB activity and monocyte chemoattractant protein-1 expression in vascular smooth muscle cells: a possible role for protein kinase C[J]. Biochem J,2000,352(3):817-826.
26. Brand K, Page S, Rogler G, et al. Activated transcription factor-Kappa B is present in the atheriosclerosis lesion[J]. J Clin Invest,1996,97(7):1715-1722.
27. Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of ciselement "decoy" against nuclear factor-kB binding site prevents myocardial infarction [J]. Nat Med,1997,3(8):894-899.
28. Erl W, Hansson GK,Martin D, et al. Nuclear factor-kB regulate induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells[J]. Cire Res,1999,84(6):668-677.
29. Autieri MV,Yue TL, Ferstein GZ, et al. Antisense oligonucleotides to the p65 subunit of NF-κB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries[J]. Biochem Biophys Res Commun,1995,213(3):827-836.
30. Bradbury DA, Newton R, Zhu YM, et al. Effect of bradykinin, TGF-β1, IL-1β and hypoxia on COX-2 expression in pulmonary artery smooth muscle cells[J]. Am J Physiol Lung Cell Mol Physiol,2002,283(4):717-725.
31. Kubota K, Okazaki J, Louie O, et al. TGF-6 stimulates collagen I in vascular smooth muscle cells via a short element in the proximal collagen promoter [J]. J Surg Res,2003,109(1):43-50.
32. Kei Yamamoto, Ryuichi Morishita , Naruya T, et al. Ribozyme oligonucleotides against transforming growth factor -Ginhibited neointimal formation after vascular injury in rat model[J]. Circulation,2000,102(15):1308-1314.
33. Smith JD, Bryant SR, Couper LL, et al. Soluble transforming growth factor-β type II receptor inhibit negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth[J]. Cir Res,1999,84(23): 1212-1222.
34. Grainger DJ, Kemp PR, Witchell CM, et al. Transforming growth factor-β decreases the rate of proliferation of rat vascular smooth muscle cells by extending the G_2 phase of the cell cycle and delays the rise in cyclic AMP before entry into M phase[J].Biochem,1994,299(4):227-235.
35.Li J,Huang SL,Guo ZG.Platelet derived growth factor stimulated vascular smooth muscle cell proliferation and its molecular mechanism[J].Scta Phamacol Sin,2000,21(27):340-344.
36.Stefroni S,Cianciolo G,Donati G,et al.Low TGF-β1 serum levels are a risk factor for atherosclerosis disease in ESRD patients[J].Kidney International,2002,61(11):324-335.
37.Dong C,Zhu C,Wang T,et al.Upregulation of PAI-1 is mediated through TGF-β/Smad pathway in transplant arteriopathy[J].Heart Lung Transplant,2002,21(9):999-1008.
38.C.A.Argmann,C.H.Van Den Diepstraten,C.G.awyez,et al.Transforming growth factor-β1 inhibits macrophage cholesteryl ester accumulation indusced by native and oxidized VLDL remnants[J].Arter.Thromb.Vasc.Biol,2001,21(25):2011-2018.
39.Sehgal I,Thompson TC.Novel regulation of type Ⅳ collagenase(matrix metalloproteinase-9 and -2)by transforming growth factor -β_1 in human prostate cancer cell line[J].Mol Biol Cell,1999,10(6):407-416.
40.Goldstein LB,Adams R,AlbertsMJ,et al.Primary prevention of ischemic stroke [J].Circulation,2006,113(24):837-924.
41.陈凤英,郭艳红,高炜.高同型半胱氨酸血症与心血管疾病[J].内蒙古医学院学报,2006,28(5):475-479.
42.Postea O,Krotz F,Henger A,et al.Stereospecific and redox-sensitive increase inmonocyte adhesion to endothelial cells by homocysteine[J].Arterioscler Thromb Vasc Biol,2006,26(3):508-513.
43.Egashira K,Zhao Q,Kataoka C,et al.Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperp lasia after periarterial injury in mice and monkeys[J].Circ Res,2002,90(11):1167-1172.
44.Blankenberg S,Barbaux S,Tiret L.Adhesion molecules and atherosclerosis[J].A therosclerosis,2003,170(2):191-203.
45.Zeng XK,Remick DG,Wang X,et al.Homocysteine induces production of monocyte chemoattractant protein-1 and interleukin-8 in cultured human whole blood[J].Circ Res,2004,25(11):1419-1425.
46.娄桂予,江渝,彭家和,等.橙皮甙抗LDL氧化及对MCP-1 mRNA转录的影响[J].第三军医大学学报,2004,26(8):717-719.
47.管秀梅,冯赞杰,钱民章.金雀异黄素对MCP-1诱导人脐静脉血管平滑肌细胞增殖及c-fos mRNA转录的影响[J].中国药理学通报,2005,21(8):943-946.
48.Chen XL,Tummala PE,Olbrych MT,et al.Angiotensin Ⅱ induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells[J].Circ Res,1998,83(9):952-959.
49.Martin T,Cardarelli PM,Parry GC,et al.Cytokine induction of monocyte chemoattractant protein-1 gene expression in humane endothelial cells depends on the cooperative action of NF-κB and AP-1[J].Eur J Pharmacol,1997,27(5):1091-1097.
50.Yla-Herttuala S,Lipton BA,Rosenfeld ME,et al.Expression of monocyte chemattractant protein-1 in macrophage rich areas of human and rabbit atherosclerotic lesions[J].Proc Natl Acad Sci USA,1991,88(12):5252-5256.
51.Lee PC,Ho IC,Lee TC.Oxidative stress mediates sodium Arsenite-induced expression of Heme oxygenase-1,monocyte chemoattractant protein-1,and interleukin-6 in vascular smooth muscle cells[J].Toxicol Sci,2005,85(1):541-550.
52.Viedt C,Vogel J,Athanasiou T,et al.Monocyte chemoat tractant protein-1induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappa B and activator protein-l[J].Arterioscler Thromb Vasc Biol,2002,22(6):914-920.
53.Braun M,Pietsch P,Felix SB,et al.Modulation of intercellular adhension molecule-1 and vascular cell adhension molecule-1 on human coronary smooth muscle cells by cytokines[J].J Mol Cell Cardiol,1995,27(12):2571-2579.
54.Nageh MF,Sandberg ET,Marotti KR,et al.Deficiency of inflammatory cell adhesion molecule protects agains atherosclerosis[J].Arterioscler Thromb Vasc Biol,1997,17(8):1517-1520.
55.Cybulsky MI,Fries JW,Williams AJ,et al.Gene structure,chromosomal location and basis for alternative mRNA splicing of the human VCAM-1 gene[J].Proc Natl Acad Sci USA,1991,88(17):7859-7863.
56.姜建青,唐旭东,赁常文,等.心肌缺血再灌注中核因子-κB活性变化及其对中性粒细胞粘附的影响[J].中国胸心血管外科临床杂志,2002,9(1):44-46.
57.Li H,Cybulsky MI,Gimbrone MA Jr,et al.Inducible expression of vascular adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma[J].Am J Pathol,1993,143(6):1551-1559.
58.陈在嘉主编.冠心病[M].北京:人民卫生出版社,2002:80-87.
59.Irizarry MC,Gurol ME,Raju S,et al.Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease[J].Neurology,2005,65(9):1402-1408.
60.雷载权等.《中药学》(第一版)[M].上海科技出版社,1995,310,204,198-199,280-281,310,220,232,98-99.
61.杨建军,胡淑婷,张焱,等.枸杞多糖对培养心肌细胞自由基损伤的超微结构的影响[J].中国中医基础杂志,2001,7(1):37-39.
62.刘秀英,胡怡秀,臧雪冰,等.枸杞油胶丸对高脂大鼠血脂水平的影响[J].中国自然医学杂志,2004,6(3):134-136.
63.黄琳娟,田庚元,王仲孚,等.枸杞子糖缀合物及其糖链对LDL氧化修饰的抑制作用[J].药学学报,2001,36(2):108-111.
64.余椿生,李慧.枸杞子[M].食品与药品,2005,7(8):62-64.
65.贾月霞,时安云.枸杞多糖对肾性高血压大鼠血管活性物质的影响[J].北京医科大学学报,1997,29(5):429-432.
66.王学美,富宏.淫羊藿、枸杞子对老年大鼠线粒体DNA缺失、线粒体呼吸链酶复合体和ATP合成的影响[J].北京大学学报(医学版),2002,34(1):68-71.
67.许涛,喻莉,郑智.丹参对实验性动脉粥样硬化形成的预防[J].临床心血管病杂志,2005,21(1):54-55.
68.张文军,包晓峰,王秀凤,等.丹参酮Ⅱ-A磺酸钠抑制巨噬细胞源性生长因子刺激平滑肌细胞c-myc基因表达[J].中国动脉硬化杂志,1996,4(1):45-47.
69.李晓红,关玉庆,邴淑丽.脑梗死早期脑循环动力学改变及复方丹参的疗效观察[J].华西药学杂志,2001,16(1):70-71.
70.孙宝华,张婉蓉,车东媛.丹参对缺氧性内皮细胞条件培养液促平滑肌细胞增生和胶原合成的影响[J].同济医科大学学报,1995,24(1):51.
71.杜俊蓉.丹参酮Ⅱ-A对培养人血管平滑肌细胞增殖的影响[J].华西药学杂志,1999,14(1):11.
72.周小明,陆再英,汪道文.丹参防治实验性动脉再狭窄及其机制的初步研究[J].中国中西医结合杂志,1996,16(8):480.
73.孟振行,朱甫祥,韩彩丽,等.丹参对实验性动脉粥样硬化预防作用的研究[J].心肺血管病杂志,1995,14(2):1011.
74.刘虹彬,温进坤.丹参对血管平滑肌细胞基质金属蛋白酶和骨桥蛋白基因表达及细胞增殖的影响[J].中国中西医结合杂志,2002,22(10):764-766.
75.李欣,杜俊蓉,张蓉,等.丹参酮防治动脉再狭窄作用的实验研究[J].中国中药杂志,2004,29(3):255-258.
76.马小干,时德.丹参对血小板源生长因子刺激血管平滑肌细胞增生的影响[J].中国普通外科杂志,2002,11(8):488-490.
77.祖淑玉,高咏梅,朱广瑾.丹参对血管紧张素Ⅱ诱导内皮细胞组织因子基因表达的作用[J].中华老年心脑血管病杂志,2004,6(4):257-260.
78.高小平,徐大勇,邓义龙,等.从丹参中筛选血管紧张素转换酶抑制剂[J].中国中药杂志,2004,29(4):359-362.
79.张知新,高福云,李克明,等.丹参酚酸B镁对自由基损伤人主动脉内皮细胞的影响[J].中国中西医结合杂志,2004,24(6):521-524.
80.林琳,郑永芳.mm-LDL激活ECV304 BK_(Ca)及丹参与川芎嗪的干预作用[J].中国医学科学院学报,2001,23(4):386-389.
81.唐中,周京国.丹参在体外对血小板FIB-R和CD62P活化的影响[J].江西医学检验,2004,2(1):39-40.
82.姜开余,顾振纶,阮长耿.丹参素对CD11b、P-Selectin、ICAM-1、VCAM-1、E-Selectin表达的影响[J].中国药理学通报,2000,16(6):682.
83.杨佳,秦彩玲.复方丹参方及丹参、三七对血小板功能影响的研究概况[J].中国实验方剂学杂志,2003,9(2):59-62.
84.严常开,刘惟莞,敖英,等.丹参素胶囊活血化瘀作用的实验研究[J].中成药,2003,25(8):637-639.
85.黄进宇,单江,徐耕,等.黄芪抑制血管平滑肌细胞增殖及其作用机制[J].中国现代应用药学杂志,2003,20(4):277.
86.韩志芬,戴薇薇,金国琴,等.加减益气聪明汤及单味黄芪药物血清对成纤维细胞胶原合成速率的影响[J].中国中医药科技,2002,9(1):51.
87.李臣鸿,刘晓晴,张珍祥,等.急性肺损伤时黄芪对核因子κB及白细胞介素mRNA表达的影响[J].中华结核和呼吸杂志,2002,25(3):189-190.
88.黄进宇,单江,程刚,等.黄芪注射液体外对大鼠血管平滑肌细胞基质金属蛋白酶-2活性的抑制作用[J].中医杂志,2003,44(2):140.
89.黄水清,韩凌,王剑,等.当归补血汤含药血清抗动脉粥样硬化的机制研究.对氧化修饰低密度脂蛋白趋化单核细胞作用的影响[J].广州中医药大学学报,2004,21(4):304.
90.张必祺,胡申江,单绮娴,等.黄芪舒张血管平滑肌的作用及机制[J].浙江大学学报(医学版),2005,24(1):65.
91.高建,徐先祥,徐先俊,等.黄芪总皂甙抗血栓形成作用的实验研究[J].中成药.2002,24(2):116-118.
92.王巧云.黄芪注射液对血瘀证兔血液流变学的影响[J].中药药理与临床,2004,20(2):19-20.
93.张萍,刘丹,李友元.黄精多糖对动脉粥样硬化家兔血清IL-6及CRP的影响[J].医学临床研究,2006,23(7):1100-1101.
94.吉中强,高晓昕,宋鲁卿,等.63种调脂中药抗人血小板聚集的实验研究[J].山东中医杂志,1998,17(8):365-367.
95.吴燊荣,李友元,肖洒.黄精多糖调脂作用的实验研究[J].中国新药杂志,2003,12(2):108-110.
96.吴燊荣,李友元,邓洪波,等.黄精多糖对糖尿病鼠的心和肾组织糖基化终产物受体mRNA表达的影响[J].中华急诊医学杂志,2004,13(4):245-247.
97.石林,蒙义文,李伟.黄精和黄精多糖药理研究[J].天然产物研究与开发,1998,11(3):67-71.
98.王红玲,张渝侯,洪艳,等.黄精多糖对小鼠血糖水平的影响及机理初探[J]. 儿科药学杂志,2002,8(1):14-15.
99.唐利龙,江丽惠,张均华,等.川芎嗪对原代培养血管平滑肌细胞胶原基因表达的影响[J].中国中西医结合杂志,1995,15(11):666.
100.严仪昭,陈祥银,吴康健,等.川芎嗪和764-3对成纤维细胞Ⅰ、Ⅱ型前胶原mRNA表达的影响[J].中国医学科学院学报,1996,18(2):126.
101.O'Brien KD,Allen MD,Mcdonald TO,et al.Vascular cell adhesion molecule-1expressed in human coronary atherosclerotic plaques:inplication for the mode of progression of advanced coronary atherosclerosis[J].J Clin Invest,1993,92(2):945-951.
102.欧阳静萍.阿魏酸钠对高脂血症家兔动脉粥样硬化形成的影响及其机制的研究[J].中国药理学通报,2002,18(4):207-210.
103.付蕾.阿魏酸钠对动脉粥样硬化鹌鹑血中NO、LPO及SOD生成的影响[J].河南医学研究,2000,9(3):217-219.
104.刘红.川芎嗪对动脉粥样硬化家兔血清一氧化氮、血浆内皮素和脂质过氧化物的影响[J].湖北民族学院学报(医学版),2000,17(4):1.
105.Hernadez-Presa M,Bustos C,Ortego M,et al.Aniotensin-converting enzyme inhibition prevents arterialnuclear factor-kappa B activation,monocyte chemoattraction protein-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis[J].Circulation,1997,95(6):1532-1541.
106.Kranzhofer R,Schmidt J,Pfeiffer CA,et al.Angiotensin induces inflammatory activation of human vascular smooth cells[J].Arterioscler Thromb Casc Biol,1999,19(7):1623-1629.
107.邓仲端,邱红明,瞿智玲.巨噬细胞源性趋化因子致平滑肌细胞迁移[J].中华病理学杂志,1993,22(5):163-165.
108.欧仕益,包惠燕,蓝志东.阿魏酸及其衍生物的药理作用研究进展[J].中药材,2001,12(8):220-221.
109.朱全刚,胡晋红,黄瑾.阿魏酸及其衍生物的药理作用[J].中药材,2001,21(7):199-200.
110.张涛,杜兰萍.水蛭和丹参对血管成形术后平滑肌细胞增殖的实验研究[J]. 中国中西医结合杂志,1998,18(3):159-161.
111.张玉娟,田景振,郭之平.水蛭研究概述[J].食品与药品,2005,7(6):9-11.
112.朱智明,刘伊丽,万华印,等.血小板膜GPⅡb/Ⅲa单抗及水蛭素对损伤动脉内膜血小板沉积量的影响[J].心肺血管病杂志,1998,17(1):39.
113.王敏,崔连群,张承俊,等.凝血酶诱导血管内皮细胞生长因子的表达及水蛭素的抑制作用[J].中国新药杂志,2004,13(3):226-230.
114.邱全,董少龙,林英辉,等.水蛭胶囊治疗脑动脉硬化症疗效观察[J].广西中医药,2004,27(3):14-16.
115.莫尚武,刘宁,张巫奎,等.瓜蒌皮提取物对大鼠主动脉PDC C_a~(2+)内流的影响[J].中草药,1999,30(9):674-676.
116.李自成,常青.瓜蒌注射液对兔血管平滑肌细胞增殖细胞核抗原表达的影响[J].中国病理生理杂志,2000,16(6):516-518.
117.蒋文跃,杨宇.化痰药半夏、瓜蒌、浙贝母、石菖蒲对大鼠血液流变性的影响[J].中医杂志,2002,43(3):215-216.
118.贺立勍.瓜蒌、薤白降脂作用的析因研究[J].湖南中医药导报,2002,8(4):205-207.
119.尹春琳,徐成斌.大黄素对血管平滑肌细胞增殖抑制作用的机制[J].中国中西医结合杂志,1998,30(6):515-517.
120.刘志红,朱加明.大黄酸对转化生长因子诱导内皮细胞纤溶酶原激活物抑制物-1表达的影响[J].中华肾脏病杂志,2002,18(5):337-341.
121.谭辉,宋开兰,刘娅.大黄对重度充血性心力衰竭患者细胞因子及氧化应激的影响[J].中国现代医学杂志,2003,13(22):99-100.
122.戴英,马建民,徐颖,等.大黄多糖对糖尿病小鼠血清脂质等几项指标的作用[J].上海实验动物科学,2004,24(2):94-96.
123.林秀珍,靳珠华.番泻苷和大黄多糖对大鼠血小板细胞内游离钙浓度的影响[J].中国药理学通报,1995,11(1):29-32.
124.黄政德,蒋孟良,易延适,等.酒制丹参、大黄对大鼠血小板功能及抗凝血作用的研究[J].中成药,2001,23(5):341.
125.熊辉岩,谭大风.大黄属三种植物不同部分提取物清除羟基自由基的体外实验研究[J].食品科学,2003,24(1):128-130.
126.徐翔郦,柏平,张慧芬.大黄的研究进展[J].上海中医药杂志,2003,37(4):56-59.
127.Li HL,Chen HL,Li H,et al.Regulatory effects of emodin on NF -kappaB activation and inflammatory cytokine expression in RAW 264.7 macrophages[J].Int J Mol Med,2005,6(1):41-47.
128.左彦方,郭毅,姜昕,等.小檗碱对兔动脉粥样硬化及其血脂的影响[J].中国脑血管病杂志,2006,3(5):204-207.
129.兰进,杨世林,郑玉权,等.黄连的研究进展[J].中草药,2001,32(12):1139-1141.
130.何国厚,艾志兵,刘勇,等.小檗碱对兔颈动脉粥样硬化中内膜增生和巨噬细胞趋化作用的影响[J].中风与神经疾病杂志,2006,23(1):94-96.
131.段浩,张宏考,刘继军,等.小檗碱对兔颈动脉损伤后白介素-6等的影响[J].医药论坛杂志,2006,27(10):6-9.
132.周岚,何国厚,李承晏,等.小檗碱对颈动脉粥样硬化家兔血管紧张素的影响[J].卒中与神经疾病,2006,13(4):212-214,218.
133.Suzuki H,Takaboshi K,Kawakami T,et al.对由炎症刺激引起的巨噬细胞和肝肿瘤细胞NO生成的抑制作用[J].和汉医药杂志,1996,13(2):165.
134.陈晓儿.综述黄连有效成分及药理作用[J].学会月刊,2002,15(4):64.
135.李金鸣,张沈丽,杨光,等.N-甲基小檗胺对豚鼠单一心室肌细胞ATP敏感钾电流的影响[J].中国药理学通报,1999,15(6):542-544.
136.陈其明,谢明智.小檗碱对正常小鼠血糖调节的影响[J].药学学报,1987,22(3):161-165.
2.Rose R.Atherosclereosis-an inflammatory disease[J].N Eng J Med,1999,340(2):115-126.
3.Wilcken DE,Wilcken B.The pathogenesis of coronary artery disease:A possible role for methionine metabolism[J].J Clin Invest,1976,57(4):1079-1082.
4.司徒镇强.细胞培养[M].西安:世界图书出版公司,2001:69-71.
5.McCully KS.Vascular pathology of homocysteinemia:Implications for the pathologenesis of arteriosclerosis[J].Am J Pathol,1969,56(1):111-128.
6.Laaksonen R,Janatuinen T.High oxidized-LDL and elevated plasma homocysteine contribute to the early reduction of myocardial flow reserve in healthy adults[J].Eur J Clin Invest,2002,32(11):795-802.
7.Boushey C.A quantitative assessment of plasma homocysteine as a risk factor for vascular disease.Probable benefits of increasing folic acid intakes[J].JAMA,1995,274(13):1049-1057.
8.Rolland PH,Friggi A,Barlatier L,et al.Hyperhomocystenemia induced vascular damage in the minipig[J].Circulation,1995,91(14):1161.
9.Morita H,Kurihara H,Yoshida S,et al.Diet-induced hyperhomocysteinemia exacerbates neointima formation in rat carotid arteries after balloon injury[J].Circulation,2001,103(1):133-139.
10.Tsai JC,Perrella MA,Yoshizumi M,et al.Promotion of vascular smooth muscle cell growth by homocysteine:a link to atherosclerosis[J].Proc Natl Acad Sci,1994,91(14):6369-6373.
11.田青平.同型半胱氨酸促平滑肌细胞增殖的信号传递途径[J].中华医学杂志,2000,80(2):25-28.
12.Graham IM,Daly LE,Refsum HM,et al.Plasma homocysteine as a risk factor for vascular disease.The European Concerted Action Project[J].JAMA,1997,277(22):1775-1781.
13.Taylor LM Jr,De Frang RD,Harris EJ Jr,et al.The association of elevated plasma homocysteine with progression of symptomatic peripheral arterial disease[J].J Vasc Surg,1991,13(1):128-136.
14.Danesh J,Lewington S.Plasma homocysteine and coronary artery disease:systematic review of published epidemiological studies[J].J Cardiovasc Risk,1998,5(4):229-232.
15.Nygard O,Vollset SE,Refsum H,et al.Total homocysteineand cardiovascular disease[J].J InternMed,1999,246(5):425-454.
16.Meleady R,Graham I.Plasma homocysteine as a cardiovascular risk factor:causal,consequential,or of no consequence[J].Nutr Rev,1999,57(10):299-305.
17.Shishodia S,Majumdar S,Banerjee S,et al.Ursolic acid inhibits nuclear factor-kappa B activation induced by carcinogenic agents through suppression of I kappaB alpha kinase and p65 phosphorylation:correlation with down-regulation of cyclooxygenase 2,matrixmetalloproteinase 9,and cyclin D1[J].Cancer Res,2003,63(15):4375-4383.
18.史剑慧,许小平,李林,等.核因子-κB活化抑制对化疗药物诱导的P388白血病细胞凋亡的影响[J].中华医学杂志,2002,82(15):1050-1053.
19.Shishodia S,Aggarwal BB.Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation,suppressesexpression of anti-apoptotic gene products,and enhances apoptosis[J].Biol Chem.2004,279(45):47148-47158.
20.Jacobsen EA,Ananieva O,Brown ML,et al.Growth,Differentiation,and Malignant Transformation of Pre-BCells Mediated by Inducible Activation of v-Abl Oncogene[J].Immunol,2006,176(11):6831-6838.
21.Silverman N,Maniatis T.NF-kappa B signaling pathways in mammalian and insect innate immunity[J].Genes Dev,2001,15(18):2321-2342.
22.Flohe L,Brigelius-Flohe R,Saliou C,et al.Packer L redox regulation of NF-kappa B activation[J].Free Raic Biol Med,1997,22(6):1115-1126.
23.May MJ,Ghosh S.Signal transduction through NF-κB[J].Immunol Today,1998,19(2):80-88.
24.Lubec B,Labudova O,Hoeger H,et al.Homocysteine increase cyclin-dependent kinase in aortic rat tissue[J].Circulation,1996,94(20):2620.
25. Wang G, Siow YL, O K. Homocysteine stimulates nuclear factor kappaB activity and monocyte chemoattractant protein-1 expression in vascular smooth muscle cells: a possible role for protein kinase C[J]. Biochem J,2000,352(3):817-826.
26. Brand K, Page S, Rogler G, et al. Activated transcription factor-Kappa B is present in the atheriosclerosis lesion[J]. J Clin Invest,1996,97(7):1715-1722.
27. Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of ciselement "decoy" against nuclear factor-kB binding site prevents myocardial infarction [J]. Nat Med,1997,3(8):894-899.
28. Erl W, Hansson GK,Martin D, et al. Nuclear factor-kB regulate induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells[J]. Cire Res,1999,84(6):668-677.
29. Autieri MV,Yue TL, Ferstein GZ, et al. Antisense oligonucleotides to the p65 subunit of NF-κB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries[J]. Biochem Biophys Res Commun,1995,213(3):827-836.
30. Bradbury DA, Newton R, Zhu YM, et al. Effect of bradykinin, TGF-β1, IL-1β and hypoxia on COX-2 expression in pulmonary artery smooth muscle cells[J]. Am J Physiol Lung Cell Mol Physiol,2002,283(4):717-725.
31. Kubota K, Okazaki J, Louie O, et al. TGF-6 stimulates collagen I in vascular smooth muscle cells via a short element in the proximal collagen promoter [J]. J Surg Res,2003,109(1):43-50.
32. Kei Yamamoto, Ryuichi Morishita , Naruya T, et al. Ribozyme oligonucleotides against transforming growth factor -Ginhibited neointimal formation after vascular injury in rat model[J]. Circulation,2000,102(15):1308-1314.
33. Smith JD, Bryant SR, Couper LL, et al. Soluble transforming growth factor-β type II receptor inhibit negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth[J]. Cir Res,1999,84(23): 1212-1222.
34. Grainger DJ, Kemp PR, Witchell CM, et al. Transforming growth factor-β decreases the rate of proliferation of rat vascular smooth muscle cells by extending the G_2 phase of the cell cycle and delays the rise in cyclic AMP before entry into M phase[J].Biochem,1994,299(4):227-235.
35.Li J,Huang SL,Guo ZG.Platelet derived growth factor stimulated vascular smooth muscle cell proliferation and its molecular mechanism[J].Scta Phamacol Sin,2000,21(27):340-344.
36.Stefroni S,Cianciolo G,Donati G,et al.Low TGF-β1 serum levels are a risk factor for atherosclerosis disease in ESRD patients[J].Kidney International,2002,61(11):324-335.
37.Dong C,Zhu C,Wang T,et al.Upregulation of PAI-1 is mediated through TGF-β/Smad pathway in transplant arteriopathy[J].Heart Lung Transplant,2002,21(9):999-1008.
38.C.A.Argmann,C.H.Van Den Diepstraten,C.G.awyez,et al.Transforming growth factor-β1 inhibits macrophage cholesteryl ester accumulation indusced by native and oxidized VLDL remnants[J].Arter.Thromb.Vasc.Biol,2001,21(25):2011-2018.
39.Sehgal I,Thompson TC.Novel regulation of type Ⅳ collagenase(matrix metalloproteinase-9 and -2)by transforming growth factor -β_1 in human prostate cancer cell line[J].Mol Biol Cell,1999,10(6):407-416.
40.Goldstein LB,Adams R,AlbertsMJ,et al.Primary prevention of ischemic stroke [J].Circulation,2006,113(24):837-924.
41.陈凤英,郭艳红,高炜.高同型半胱氨酸血症与心血管疾病[J].内蒙古医学院学报,2006,28(5):475-479.
42.Postea O,Krotz F,Henger A,et al.Stereospecific and redox-sensitive increase inmonocyte adhesion to endothelial cells by homocysteine[J].Arterioscler Thromb Vasc Biol,2006,26(3):508-513.
43.Egashira K,Zhao Q,Kataoka C,et al.Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperp lasia after periarterial injury in mice and monkeys[J].Circ Res,2002,90(11):1167-1172.
44.Blankenberg S,Barbaux S,Tiret L.Adhesion molecules and atherosclerosis[J].A therosclerosis,2003,170(2):191-203.
45.Zeng XK,Remick DG,Wang X,et al.Homocysteine induces production of monocyte chemoattractant protein-1 and interleukin-8 in cultured human whole blood[J].Circ Res,2004,25(11):1419-1425.
46.娄桂予,江渝,彭家和,等.橙皮甙抗LDL氧化及对MCP-1 mRNA转录的影响[J].第三军医大学学报,2004,26(8):717-719.
47.管秀梅,冯赞杰,钱民章.金雀异黄素对MCP-1诱导人脐静脉血管平滑肌细胞增殖及c-fos mRNA转录的影响[J].中国药理学通报,2005,21(8):943-946.
48.Chen XL,Tummala PE,Olbrych MT,et al.Angiotensin Ⅱ induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells[J].Circ Res,1998,83(9):952-959.
49.Martin T,Cardarelli PM,Parry GC,et al.Cytokine induction of monocyte chemoattractant protein-1 gene expression in humane endothelial cells depends on the cooperative action of NF-κB and AP-1[J].Eur J Pharmacol,1997,27(5):1091-1097.
50.Yla-Herttuala S,Lipton BA,Rosenfeld ME,et al.Expression of monocyte chemattractant protein-1 in macrophage rich areas of human and rabbit atherosclerotic lesions[J].Proc Natl Acad Sci USA,1991,88(12):5252-5256.
51.Lee PC,Ho IC,Lee TC.Oxidative stress mediates sodium Arsenite-induced expression of Heme oxygenase-1,monocyte chemoattractant protein-1,and interleukin-6 in vascular smooth muscle cells[J].Toxicol Sci,2005,85(1):541-550.
52.Viedt C,Vogel J,Athanasiou T,et al.Monocyte chemoat tractant protein-1induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappa B and activator protein-l[J].Arterioscler Thromb Vasc Biol,2002,22(6):914-920.
53.Braun M,Pietsch P,Felix SB,et al.Modulation of intercellular adhension molecule-1 and vascular cell adhension molecule-1 on human coronary smooth muscle cells by cytokines[J].J Mol Cell Cardiol,1995,27(12):2571-2579.
54.Nageh MF,Sandberg ET,Marotti KR,et al.Deficiency of inflammatory cell adhesion molecule protects agains atherosclerosis[J].Arterioscler Thromb Vasc Biol,1997,17(8):1517-1520.
55.Cybulsky MI,Fries JW,Williams AJ,et al.Gene structure,chromosomal location and basis for alternative mRNA splicing of the human VCAM-1 gene[J].Proc Natl Acad Sci USA,1991,88(17):7859-7863.
56.姜建青,唐旭东,赁常文,等.心肌缺血再灌注中核因子-κB活性变化及其对中性粒细胞粘附的影响[J].中国胸心血管外科临床杂志,2002,9(1):44-46.
57.Li H,Cybulsky MI,Gimbrone MA Jr,et al.Inducible expression of vascular adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma[J].Am J Pathol,1993,143(6):1551-1559.
58.陈在嘉主编.冠心病[M].北京:人民卫生出版社,2002:80-87.
59.Irizarry MC,Gurol ME,Raju S,et al.Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease[J].Neurology,2005,65(9):1402-1408.
60.雷载权等.《中药学》(第一版)[M].上海科技出版社,1995,310,204,198-199,280-281,310,220,232,98-99.
61.杨建军,胡淑婷,张焱,等.枸杞多糖对培养心肌细胞自由基损伤的超微结构的影响[J].中国中医基础杂志,2001,7(1):37-39.
62.刘秀英,胡怡秀,臧雪冰,等.枸杞油胶丸对高脂大鼠血脂水平的影响[J].中国自然医学杂志,2004,6(3):134-136.
63.黄琳娟,田庚元,王仲孚,等.枸杞子糖缀合物及其糖链对LDL氧化修饰的抑制作用[J].药学学报,2001,36(2):108-111.
64.余椿生,李慧.枸杞子[M].食品与药品,2005,7(8):62-64.
65.贾月霞,时安云.枸杞多糖对肾性高血压大鼠血管活性物质的影响[J].北京医科大学学报,1997,29(5):429-432.
66.王学美,富宏.淫羊藿、枸杞子对老年大鼠线粒体DNA缺失、线粒体呼吸链酶复合体和ATP合成的影响[J].北京大学学报(医学版),2002,34(1):68-71.
67.许涛,喻莉,郑智.丹参对实验性动脉粥样硬化形成的预防[J].临床心血管病杂志,2005,21(1):54-55.
68.张文军,包晓峰,王秀凤,等.丹参酮Ⅱ-A磺酸钠抑制巨噬细胞源性生长因子刺激平滑肌细胞c-myc基因表达[J].中国动脉硬化杂志,1996,4(1):45-47.
69.李晓红,关玉庆,邴淑丽.脑梗死早期脑循环动力学改变及复方丹参的疗效观察[J].华西药学杂志,2001,16(1):70-71.
70.孙宝华,张婉蓉,车东媛.丹参对缺氧性内皮细胞条件培养液促平滑肌细胞增生和胶原合成的影响[J].同济医科大学学报,1995,24(1):51.
71.杜俊蓉.丹参酮Ⅱ-A对培养人血管平滑肌细胞增殖的影响[J].华西药学杂志,1999,14(1):11.
72.周小明,陆再英,汪道文.丹参防治实验性动脉再狭窄及其机制的初步研究[J].中国中西医结合杂志,1996,16(8):480.
73.孟振行,朱甫祥,韩彩丽,等.丹参对实验性动脉粥样硬化预防作用的研究[J].心肺血管病杂志,1995,14(2):1011.
74.刘虹彬,温进坤.丹参对血管平滑肌细胞基质金属蛋白酶和骨桥蛋白基因表达及细胞增殖的影响[J].中国中西医结合杂志,2002,22(10):764-766.
75.李欣,杜俊蓉,张蓉,等.丹参酮防治动脉再狭窄作用的实验研究[J].中国中药杂志,2004,29(3):255-258.
76.马小干,时德.丹参对血小板源生长因子刺激血管平滑肌细胞增生的影响[J].中国普通外科杂志,2002,11(8):488-490.
77.祖淑玉,高咏梅,朱广瑾.丹参对血管紧张素Ⅱ诱导内皮细胞组织因子基因表达的作用[J].中华老年心脑血管病杂志,2004,6(4):257-260.
78.高小平,徐大勇,邓义龙,等.从丹参中筛选血管紧张素转换酶抑制剂[J].中国中药杂志,2004,29(4):359-362.
79.张知新,高福云,李克明,等.丹参酚酸B镁对自由基损伤人主动脉内皮细胞的影响[J].中国中西医结合杂志,2004,24(6):521-524.
80.林琳,郑永芳.mm-LDL激活ECV304 BK_(Ca)及丹参与川芎嗪的干预作用[J].中国医学科学院学报,2001,23(4):386-389.
81.唐中,周京国.丹参在体外对血小板FIB-R和CD62P活化的影响[J].江西医学检验,2004,2(1):39-40.
82.姜开余,顾振纶,阮长耿.丹参素对CD11b、P-Selectin、ICAM-1、VCAM-1、E-Selectin表达的影响[J].中国药理学通报,2000,16(6):682.
83.杨佳,秦彩玲.复方丹参方及丹参、三七对血小板功能影响的研究概况[J].中国实验方剂学杂志,2003,9(2):59-62.
84.严常开,刘惟莞,敖英,等.丹参素胶囊活血化瘀作用的实验研究[J].中成药,2003,25(8):637-639.
85.黄进宇,单江,徐耕,等.黄芪抑制血管平滑肌细胞增殖及其作用机制[J].中国现代应用药学杂志,2003,20(4):277.
86.韩志芬,戴薇薇,金国琴,等.加减益气聪明汤及单味黄芪药物血清对成纤维细胞胶原合成速率的影响[J].中国中医药科技,2002,9(1):51.
87.李臣鸿,刘晓晴,张珍祥,等.急性肺损伤时黄芪对核因子κB及白细胞介素mRNA表达的影响[J].中华结核和呼吸杂志,2002,25(3):189-190.
88.黄进宇,单江,程刚,等.黄芪注射液体外对大鼠血管平滑肌细胞基质金属蛋白酶-2活性的抑制作用[J].中医杂志,2003,44(2):140.
89.黄水清,韩凌,王剑,等.当归补血汤含药血清抗动脉粥样硬化的机制研究.对氧化修饰低密度脂蛋白趋化单核细胞作用的影响[J].广州中医药大学学报,2004,21(4):304.
90.张必祺,胡申江,单绮娴,等.黄芪舒张血管平滑肌的作用及机制[J].浙江大学学报(医学版),2005,24(1):65.
91.高建,徐先祥,徐先俊,等.黄芪总皂甙抗血栓形成作用的实验研究[J].中成药.2002,24(2):116-118.
92.王巧云.黄芪注射液对血瘀证兔血液流变学的影响[J].中药药理与临床,2004,20(2):19-20.
93.张萍,刘丹,李友元.黄精多糖对动脉粥样硬化家兔血清IL-6及CRP的影响[J].医学临床研究,2006,23(7):1100-1101.
94.吉中强,高晓昕,宋鲁卿,等.63种调脂中药抗人血小板聚集的实验研究[J].山东中医杂志,1998,17(8):365-367.
95.吴燊荣,李友元,肖洒.黄精多糖调脂作用的实验研究[J].中国新药杂志,2003,12(2):108-110.
96.吴燊荣,李友元,邓洪波,等.黄精多糖对糖尿病鼠的心和肾组织糖基化终产物受体mRNA表达的影响[J].中华急诊医学杂志,2004,13(4):245-247.
97.石林,蒙义文,李伟.黄精和黄精多糖药理研究[J].天然产物研究与开发,1998,11(3):67-71.
98.王红玲,张渝侯,洪艳,等.黄精多糖对小鼠血糖水平的影响及机理初探[J]. 儿科药学杂志,2002,8(1):14-15.
99.唐利龙,江丽惠,张均华,等.川芎嗪对原代培养血管平滑肌细胞胶原基因表达的影响[J].中国中西医结合杂志,1995,15(11):666.
100.严仪昭,陈祥银,吴康健,等.川芎嗪和764-3对成纤维细胞Ⅰ、Ⅱ型前胶原mRNA表达的影响[J].中国医学科学院学报,1996,18(2):126.
101.O'Brien KD,Allen MD,Mcdonald TO,et al.Vascular cell adhesion molecule-1expressed in human coronary atherosclerotic plaques:inplication for the mode of progression of advanced coronary atherosclerosis[J].J Clin Invest,1993,92(2):945-951.
102.欧阳静萍.阿魏酸钠对高脂血症家兔动脉粥样硬化形成的影响及其机制的研究[J].中国药理学通报,2002,18(4):207-210.
103.付蕾.阿魏酸钠对动脉粥样硬化鹌鹑血中NO、LPO及SOD生成的影响[J].河南医学研究,2000,9(3):217-219.
104.刘红.川芎嗪对动脉粥样硬化家兔血清一氧化氮、血浆内皮素和脂质过氧化物的影响[J].湖北民族学院学报(医学版),2000,17(4):1.
105.Hernadez-Presa M,Bustos C,Ortego M,et al.Aniotensin-converting enzyme inhibition prevents arterialnuclear factor-kappa B activation,monocyte chemoattraction protein-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis[J].Circulation,1997,95(6):1532-1541.
106.Kranzhofer R,Schmidt J,Pfeiffer CA,et al.Angiotensin induces inflammatory activation of human vascular smooth cells[J].Arterioscler Thromb Casc Biol,1999,19(7):1623-1629.
107.邓仲端,邱红明,瞿智玲.巨噬细胞源性趋化因子致平滑肌细胞迁移[J].中华病理学杂志,1993,22(5):163-165.
108.欧仕益,包惠燕,蓝志东.阿魏酸及其衍生物的药理作用研究进展[J].中药材,2001,12(8):220-221.
109.朱全刚,胡晋红,黄瑾.阿魏酸及其衍生物的药理作用[J].中药材,2001,21(7):199-200.
110.张涛,杜兰萍.水蛭和丹参对血管成形术后平滑肌细胞增殖的实验研究[J]. 中国中西医结合杂志,1998,18(3):159-161.
111.张玉娟,田景振,郭之平.水蛭研究概述[J].食品与药品,2005,7(6):9-11.
112.朱智明,刘伊丽,万华印,等.血小板膜GPⅡb/Ⅲa单抗及水蛭素对损伤动脉内膜血小板沉积量的影响[J].心肺血管病杂志,1998,17(1):39.
113.王敏,崔连群,张承俊,等.凝血酶诱导血管内皮细胞生长因子的表达及水蛭素的抑制作用[J].中国新药杂志,2004,13(3):226-230.
114.邱全,董少龙,林英辉,等.水蛭胶囊治疗脑动脉硬化症疗效观察[J].广西中医药,2004,27(3):14-16.
115.莫尚武,刘宁,张巫奎,等.瓜蒌皮提取物对大鼠主动脉PDC C_a~(2+)内流的影响[J].中草药,1999,30(9):674-676.
116.李自成,常青.瓜蒌注射液对兔血管平滑肌细胞增殖细胞核抗原表达的影响[J].中国病理生理杂志,2000,16(6):516-518.
117.蒋文跃,杨宇.化痰药半夏、瓜蒌、浙贝母、石菖蒲对大鼠血液流变性的影响[J].中医杂志,2002,43(3):215-216.
118.贺立勍.瓜蒌、薤白降脂作用的析因研究[J].湖南中医药导报,2002,8(4):205-207.
119.尹春琳,徐成斌.大黄素对血管平滑肌细胞增殖抑制作用的机制[J].中国中西医结合杂志,1998,30(6):515-517.
120.刘志红,朱加明.大黄酸对转化生长因子诱导内皮细胞纤溶酶原激活物抑制物-1表达的影响[J].中华肾脏病杂志,2002,18(5):337-341.
121.谭辉,宋开兰,刘娅.大黄对重度充血性心力衰竭患者细胞因子及氧化应激的影响[J].中国现代医学杂志,2003,13(22):99-100.
122.戴英,马建民,徐颖,等.大黄多糖对糖尿病小鼠血清脂质等几项指标的作用[J].上海实验动物科学,2004,24(2):94-96.
123.林秀珍,靳珠华.番泻苷和大黄多糖对大鼠血小板细胞内游离钙浓度的影响[J].中国药理学通报,1995,11(1):29-32.
124.黄政德,蒋孟良,易延适,等.酒制丹参、大黄对大鼠血小板功能及抗凝血作用的研究[J].中成药,2001,23(5):341.
125.熊辉岩,谭大风.大黄属三种植物不同部分提取物清除羟基自由基的体外实验研究[J].食品科学,2003,24(1):128-130.
126.徐翔郦,柏平,张慧芬.大黄的研究进展[J].上海中医药杂志,2003,37(4):56-59.
127.Li HL,Chen HL,Li H,et al.Regulatory effects of emodin on NF -kappaB activation and inflammatory cytokine expression in RAW 264.7 macrophages[J].Int J Mol Med,2005,6(1):41-47.
128.左彦方,郭毅,姜昕,等.小檗碱对兔动脉粥样硬化及其血脂的影响[J].中国脑血管病杂志,2006,3(5):204-207.
129.兰进,杨世林,郑玉权,等.黄连的研究进展[J].中草药,2001,32(12):1139-1141.
130.何国厚,艾志兵,刘勇,等.小檗碱对兔颈动脉粥样硬化中内膜增生和巨噬细胞趋化作用的影响[J].中风与神经疾病杂志,2006,23(1):94-96.
131.段浩,张宏考,刘继军,等.小檗碱对兔颈动脉损伤后白介素-6等的影响[J].医药论坛杂志,2006,27(10):6-9.
132.周岚,何国厚,李承晏,等.小檗碱对颈动脉粥样硬化家兔血管紧张素的影响[J].卒中与神经疾病,2006,13(4):212-214,218.
133.Suzuki H,Takaboshi K,Kawakami T,et al.对由炎症刺激引起的巨噬细胞和肝肿瘤细胞NO生成的抑制作用[J].和汉医药杂志,1996,13(2):165.
134.陈晓儿.综述黄连有效成分及药理作用[J].学会月刊,2002,15(4):64.
135.李金鸣,张沈丽,杨光,等.N-甲基小檗胺对豚鼠单一心室肌细胞ATP敏感钾电流的影响[J].中国药理学通报,1999,15(6):542-544.
136.陈其明,谢明智.小檗碱对正常小鼠血糖调节的影响[J].药学学报,1987,22(3):161-165.